Version 1
: Received: 1 August 2024 / Approved: 1 August 2024 / Online: 2 August 2024 (05:54:13 CEST)
How to cite:
Chung-Chieh, H.; Ying-Chin, K.; Ping-Ho, C.; Chia-Min, C. Evaluation of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel-Quid Use Disorder. Preprints2024, 2024080036. https://doi.org/10.20944/preprints202408.0036.v1
Chung-Chieh, H.; Ying-Chin, K.; Ping-Ho, C.; Chia-Min, C. Evaluation of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel-Quid Use Disorder. Preprints 2024, 2024080036. https://doi.org/10.20944/preprints202408.0036.v1
Chung-Chieh, H.; Ying-Chin, K.; Ping-Ho, C.; Chia-Min, C. Evaluation of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel-Quid Use Disorder. Preprints2024, 2024080036. https://doi.org/10.20944/preprints202408.0036.v1
APA Style
Chung-Chieh, H., Ying-Chin, K., Ping-Ho, C., & Chia-Min, C. (2024). Evaluation of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel-Quid Use Disorder. Preprints. https://doi.org/10.20944/preprints202408.0036.v1
Chicago/Turabian Style
Chung-Chieh, H., Chen Ping-Ho and Chung Chia-Min. 2024 "Evaluation of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel-Quid Use Disorder" Preprints. https://doi.org/10.20944/preprints202408.0036.v1
Abstract
Betel quid (BQ) use disorder (BUD) is prevalent in many Asian countries, impacting approximately 600 million people. We conducted a randomized clinical trial to analyze the impact of MAOA genetic variations on the severity of BQ craving. This was measured using DSM-5 criteria and Yale-Brown Obsessive Compulsive Scale modified for betel-quid (Y-BOCS-BQ). Participants were grouped according to the severity of BUD and MAOA gene single nucleotide polymorphism (SNP) rs5953210 genotypes. Y-BOCS-BQ were assessed at baseline (week 0) and during follow-up at weeks 2, 4, 6, and 8. The AA genotype group showed significantly greater reductions in Y-BOCS-BQ at weeks 2 (p=0.0194), 4 (p=0.0078), 6 (p=0.0277), and 8 (p=0.0376) compared to the GG genotype group. Additionally, within the antidepressant group, the AA genotype showed significant reductions in Y-BOCS-BQ at weeks 2 (p=0.0313), 4 (p=0.0134), 6 (p=0.0061), and 8 (p=0.0241) compared to the GG genotype. Statistical analysis revealed a significant interaction between the treatment and placebo groups based on MAOA genotypes, with the AA genotype in the treatment group exhibiting a more pronounced decrease in Y-BOCS-BQ (p interaction
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
